Cytostatic agent which has potent antileukemic activity both in vitro and in vivo (mice). Also displays antibacterial and antifungal activities against a limited range of microorganisms.
Product Details
| Formula: | C21H28O2 |
| |
| MW: | 312.5 |
| |
| Source: | Isolated from marine sponge Dysidea avara. |
| |
| CAS: | 55303-99-6 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Identity: | Determined by 1H-NMR, 13C-NMR and MS. |
| |
| Appearance: | Brown oil. |
| |
| Solubility: | Soluble in DMSO or 100% ethanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Evaluation of the activity of the sponge metabolites avarol and avarone and their synthetic derivatives against fouling micro- and macroorganisms: M. Tsoukatou, et al.; Molecules
12, 1022 (2007),
Abstract;
Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line: M. Amigo, et al.; J. Nat. Prod.
67, 1459 (2004),
Abstract;
Protein covalent modification by biologically active quinones: D. Sladic, et al.; J. Serb. Chem. Soc. 69, 901 (2004),
Sustainable production of bioactive compounds by sponges--cell culture and gene cluster approach: a review: W.E. Muller, et al.; Mar. Biotechnol. (NY)
6, 105 (2004),
Abstract;
In vitro effect of avarone and avarol, a quinone/hydroquinone couple of marine origin, on platelet aggregation: M.A. Belisario, et al.; Pharmacol. Toxicol.
79, 300 (1996),
Abstract;
Avarol and avarone, two new anti-inflammatory agents of marine origin: M.L. Ferrandiz, et al.; Eur. J. Pharmacol.
253, 75 (1994),
Abstract;
Effect of avarol and avarone on in vitro-induced microsomal lipid peroxidation: M.A. Belisario, et al.; Toxicology
72, 221 (1992),
Abstract;
The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives: S. Loya and A. Hizi; FEBS Lett.
269, 131 (1990),
Abstract;
Suppression of the modulatory effects of the antileukemic and anti-human immunodeficiency virus compound avarol on gene expression by tryptophan: H.C. Schroder, et al.; Cancer Res.
49, 2069 (1989),
Abstract;
Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone: P.S. Sarin, et al.; J. Natl. Cancer Inst.
78, 663 (1987),
Abstract;
Biphasic and differential effects of the cytostatic agents avarone and avarol on DNA metabolism of human and murine T and B lymphocytes: W.E. Muller, et al.; Eur. J. Cancer Clin. Oncol.
22, 473 (1986),
Abstract;
Antimutagenic activity of the novel antileukemic agents, avarone and avarol: B. Kurelec, et al.; Mutat. Res.
144, 63 (1985),
Abstract;
Potent antileukemic activity of the novel cytostatic agent avarone and its analogues in vitro and in vivo: W.E. Muller, et al.; Cancer Res.
45, 4822 (1985),
Abstract;
